...
首页> 外文期刊>The biochemical journal >Development of a high-affinity peptide that prevents phospholemman (PLM) inhibition of the sodium/calcium exchanger 1 (NCX1)
【24h】

Development of a high-affinity peptide that prevents phospholemman (PLM) inhibition of the sodium/calcium exchanger 1 (NCX1)

机译:开发一种高亲和力肽段,该肽段可防止磷酸lemman(PLM)抑制钠/钙交换剂1(NCX1)

获取原文

摘要

NCX1 (Na+/Ca2+ exchanger 1) is an important regulator of intracellular Ca2+ and a potential therapeutic target for brain ischaemia and for diastolic heart failure with preserved ejection fraction. PLM (phospholemman), a substrate for protein kinases A and C, has been suggested to regulate NCX1 activity. However, although several studies have demonstrated that binding of phosphorylated PLM (pSer68-PLM) leads to NCX1 inhibition, other studies have failed to demonstrate a functional interaction of these proteins. In the present study, we aimed to analyse the biological function of the pSer68-PLM–NCX1 interaction by developing high-affinity blocking peptides. PLM was observed to co-fractionate and co-immunoprecipitate with NCX1?in rat left ventricle, and in co-transfected HEK (human embryonic kidney)-293 cells. For the first time, the NCX1–PLM interaction was also demonstrated in the brain. PLM binding sites on NCX1 were mapped to two regions by peptide array assays, containing the previously reported PASKT and QKHPD motifs. Conversely, the two NCX1 regions bound identical sequences in the cytoplasmic domain of PLM, suggesting that NCX1-PASKT and NCX1-QKHPD might bind to each PLM monomer. Using two-dimensional peptide arrays of the native NCX1 sequence KHPDKEIEQLIELANYQVLS revealed that double substitution of tyrosine for positions 1 and 4 (K1Y and D4Y) enhanced pSer68-PLM binding 8-fold. The optimized peptide blocked binding of NCX1-PASKT and NCX1-QKHPD to PLM and reversed PLM(S68D) inhibition of NCX1 activity (both forward and reverse mode) in HEK-293 cells. Altogether our data indicate that PLM interacts directly with NCX1 and inhibits NCX1 activity when phosphorylated at Ser68.* CBD, : calcium-binding domain; CLD, : catenin-like domain; DMEM, : Dulbecco's modified Eagle's medium; GAPDH, : glyceraldehyde-3-phosphate dehydrogenase; HF, : heart failure; NCX, : Na+/Ca2+ exchanger; HRP, : horseradish peroxidase; LV, : left ventricle; NKA, : Na+/K+-ATPase; PKC, : protein kinase C; PLM, : phospholemman; SLC8, : solute carrier 8; TBS-T, : TBS with 0.1% Tween 20; TF, : trigger factor; TM, : transmembrane segment; XIP, : exchanger inhibitory peptide
机译:NCX1(Na + / Ca2 +交换剂1)是细胞内Ca2 +的重要调节剂,是脑缺血和舒张性心力衰竭且射血分数得以保留的潜在治疗靶标。已建议PLM(磷脂酶)是蛋白激酶A和C的底物,可调节NCX1活性。但是,尽管一些研究表明磷酸化的PLM(pSer68-PLM)的结合会导致NCX1抑制,但其他研究未能证明这些蛋白质的功能相互作用。在本研究中,我们旨在通过开发高亲和力阻断肽来分析pSer68-PLM-NCX1相互作用的生物学功能。在大鼠左心室和共转染的HEK(人类胚胎肾脏)-293细胞中,观察到PLM与NCX1α共分离和共免疫沉淀。首次在大脑中也证实了NCX1-PLM的相互作用。通过肽阵列分析,将NCX1上的PLM结合位点定位到两个区域,其中包含先前报道的PASKT和QKHPD基序。相反,两个NCX1区在PLM的胞质域中结合相同的序列,这表明NCX1-PASKT和NCX1-QKHPD可能与每个PLM单体结合。使用天然NCX1序列的二维肽阵列,KHPDKEIEQLIELANYQVLS显示酪氨酸在位置1和4(K1Y和D4Y)的双重取代将pSer68-PLM结合提高了8倍。优化的肽阻断了HEK-293细胞中NCX1-PASKT和NCX1-QKHPD与PLM的结合,并逆转了PLM(S68D)对NCX1活性的抑制(正向和反向模式)。总的来说,我们的数据表明当在Ser68处磷酸化时,PLM直接与NCX1相互作用并抑制NCX1活性。 CLD:连环蛋白样结构域; DMEM ,: Dulbecco改良的Eagle培养基; GAPDH ,: 3-磷酸甘油醛脱氢酶; HF ,:心力衰竭; NCX:Na + / Ca2 +交换剂; HRP:辣根过氧化物酶; LV ,:左心室; NKA:Na + / K + -ATPase; PKC ,:蛋白激酶C; PLM,:phospholemman; SLC8 ,:溶质载体8; TBS-T,:TBS,含0.1%吐温20; TF ,:触发因素; TM ,:跨膜片段; XIP:交换抑制肽

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号